The vaccine may be approved for use in China by mid-2021. - Reuters
SHANGHAI (Reuters): AstraZeneca plans to start early and mid-stage clinical trials of its Covid-19 vaccine candidate in China this year, a senior executive said on Friday (Nov 6), as it prepares a global rollout of the vaccine.
The vaccine candidate is already in the final stage of clinical trials in other countries, and AstraZeneca and its partner on the project, the University of Oxford, expect data from the late-stage trials this year.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
